Literature DB >> 16773391

Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies.

M E Falagas1, K E Apostolou, V D Pappas.   

Abstract

A systematic review of matched cohort and case-control studies was performed to examine the mortality attributable to candidemia. The review included studies that compared mortality of patients with candidemia (cases) to that of matched patients without candidemia (controls). Secondary variables examined were the length and cost of hospital stay. Relevant studies were identified using the PubMed database and by examining the references of the initially selected studies. Two independent reviewers performed the literature search, study selection and data extraction from the identified studies. A total of seven studies were included in the review. The patients included those hospitalized in intensive care units (ICU) and hospital wards and those undergoing transplantation. The mortality attributed to candidemia in the reviewed studies ranged from 5 to 71%. For six of the reviewed studies the difference in mortality between cases and controls was statistically significant. Among those who survived, the length of stay and the cost of hospitalization of patients with candidemia were significantly higher than those of controls. Despite the methodological heterogeneity of the reviewed studies, the data from the available matched cohort and case-control studies suggest that candidemia is associated with considerable mortality that is attributed, at least to some degree, to the infection itself and not only to the presence of another comorbidity.

Entities:  

Mesh:

Year:  2006        PMID: 16773391     DOI: 10.1007/s10096-006-0159-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies.

Authors:  S I Blot; K H Vandewoude
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

2.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

3.  Effects of nosocomial candidemia on outcomes of critically ill patients.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Am J Med       Date:  2002-10-15       Impact factor: 4.965

4.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

5.  The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit.

Authors:  B Digiovine; C Chenoweth; C Watts; M Higgins
Journal:  Am J Respir Crit Care Med       Date:  1999-09       Impact factor: 21.405

6.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 7.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species.

Authors:  W R Jarvis
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

Review 10.  Impact of the changing epidemiology of fungal infections in the 1990s.

Authors:  M Pfaller; R Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

View more
  84 in total

1.  Increased susceptibility to Candida infection following cecal ligation and puncture.

Authors:  Christopher G Davis; Kathy Chang; Dale Osborne; Andrew H Walton; W Michael Dunne; Jared T Muenzer
Journal:  Biochem Biophys Res Commun       Date:  2011-09-12       Impact factor: 3.575

Review 2.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 3.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 4.  Clinical aspects of invasive candidiasis in critically ill patients.

Authors:  Mariano Pennisi; Massimo Antonelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Authors:  He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 6.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

7.  Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections.

Authors:  Cassandra Moran; Chelsea A Grussemeyer; James R Spalding; Daniel K Benjamin; Shelby D Reed
Journal:  Am J Infect Control       Date:  2010-02       Impact factor: 2.918

8.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

9.  Clinical characteristics and risk factors for nosocomial candidemia in medical intensive care units: experience in a single hospital in Korea for 6.6 years.

Authors:  Seon-Sook Han; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Sang-Min Lee
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

10.  Candidemia on presentation to the hospital: development and validation of a risk score.

Authors:  Andrew F Shorr; Ying P Tabak; Richard S Johannes; Xiaowu Sun; James Spalding; Marin H Kollef
Journal:  Crit Care       Date:  2009-09-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.